interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Encorafenib

Generic competition · all medicines · read 12 November 2026

Is there a generic of Encorafenib, and who makes it?

Encorafenib appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Encorafenib1 dosage-form group in the Orange Book
0generic makers listed
  1. Encorafenib appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Capsule, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Braftovi. No generic is listed as marketed.

2015202020252030203501brand 2018data datePatent 8946250 listed to expire 23 July 2029Patent 8541575 listed to expire 26 February 2030Patent RE49556 listed to expire 27 February 2030Patent 10005761 listed to expire 27 August 2030Patent 9850230 listed to expire 27 August 2030Patent 9850229 listed to expire 27 August 2030Patent 9593099 listed to expire 27 August 2030Patent 9593100 listed to expire 27 August 2030Patent 9314464 listed to expire 4 July 2031Patent 9763941 listed to expire 21 November 2032Patent 10258622 listed to expire 21 November 2032Patent 9387208 listed to expire 21 November 2032Patent 9474754 listed to expire 5 August 2033Exclusivity I-957 to 20 December 2027Exclusivity I-997 to 24 February 2029Exclusivity ODE-445 to 11 October 2030
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 20 December 2027Exclusivity I-957 Braftovi
  • 24 February 2029Exclusivity I-997 Braftovi
  • 11 October 2030Exclusivity ODE-445 Braftovi
  • 23 July 2029Patent 8946250 drug substance
  • 26 February 2030Patent 8541575 drug substance
  • 27 February 2030Patent RE49556 drug substance
  • 27 August 2030Patent 10005761
  • 27 August 2030Patent 9850230
  • 27 August 2030Patent 9850229
  • 27 August 2030Patent 9593099 drug substance
  • 27 August 2030Patent 9593100 drug product

5 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.